The role of antiangiogenic agents continues to evolve in the treatment of CNS cancers, attendees were told in a poster discussion session at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting.
A personalized testing method may quickly and more accurately predict the effectiveness of a treatment for multiple myeloma in individual patients. The process may also aid patients with leukemia or lymphoma.
Research indicates that adjustment of imatinib doses based on therapeutic drug monitoring can result in higher rates of major molecular response in patients with newly diagnosed chronic myeloid leukemia (CML) in the chronic phase.
Eight of 14 patients in the first clinical trial of personalized cellular therapy for chronic lymphocytic leukemia (CLL) responded to the therapy, with some complete remissions continuing beyond 4.5 years.
Researchers developed a way to personalize treatments for aggressive bladder cancer. Taking bladder tumors from individual patients, identifying actionable mutations, and grafting the tumors into mice, researchers were able to simultaneously test multiple therapies in the tumor models.
Results are in from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients' tumors rather than where their cancer originated.
Researchers examined patient participation in the genomic analysis portion of clinical trials.
An increased understanding of how a certain tumor suppressor molecule works to prevent tumor growth may open the door to a personalized treatment approach for colon cancer.
New research indicates that many genetic alterations identified using tumor-only sequencing are not actually associated with the cancer, but instead reflect inherited germline mutations already present in the normal cells of the person.
An early stage trial for mesothelioma and pancreatic and ovarian cancers has explored utilizing a patient's own immune cells, genetically modified to target tumors.
Adrenal cancer is among the more rare and aggressive forms of cancer, but new research indicates the possibility of personalized treatment.
A subset of adrenal cancer patients responded well to drug treatment in a phase 3 trial, giving some hope for addressing this aggressive form of cancer.
The use of 3D printing to construct devices of varied sizes and shapes could become a powerful tool in customizing interventional radiology treatments to individual patient needs.
New animal models have been developed that allow for improved parallel tumor progression and can help clinicians predict relapses and treatment effectiveness.
Pediatric patients with acute lymphoblastic leukemia (ALL) showed a 90% response rate from the first trials testing an investigational personalized cellular therapy known as CTL019.
The possibilities for personalized vaccines in all types of cancer were explored at the European Society for Medical Oncology Symposium on Immuno-Oncology 2014.
A genetic test has been developed to identify which men are at higher risk for prostate cancer recurrence after localized treatment with surgery or radiotherapy.
Circulating tumor cells captured with a microchip-based device can be cultured to establish cell lines for genetic analysis and drug testing.
The era of personalized medicine for breast cancer may be just around the corner, thanks to recent advances by USC Stem Cell researcher Min Yu and scientists at Massachusetts General Hospital and Harvard Medical School.
Final results from a phase 2 study show that adding Prophage autologous cancer vaccine to the standard-of-care treatment for newly diagnosed GBM improves survival.
Researchers have developed a process to analyze mutated genes in lung adenocarcinoma to help better select personalized treatment options for patients.
With accelerating development of personalized cancer treatments matched to a patient's DNA sequencing, proponents of these treatments say frontline physicians increasingly need help finding the best individualized therapy.
In a new study, researchers examined the largest collection of tumor samples to date to predict patient-specific tumor mutations that may activate the patient's immune system, paving the way for more successful, personalized cancer immunotherapy.
A new predictive tool is being developed that could help patients with breast cancer and certain lung cancers decide whether follow-up treatments are likely to help.
Two studies provide new insight into a germline epidermal growth factor receptor T790M mutation in familial non-small cell lung cancer, and suggest the need for tailored approaches for early detection and treatment.
Using genomic analysis to study cancer in dogs can help develop new therapies for humans with cancer, according to a proof-of-concept study.
Researchers have developed a biologic drug that would prevent the production of a protein known to allow ovarian cancer cells to grow aggressively while being resistant to chemotherapy.
Assessing the route to cancer on a case-by-case basis might make more sense than basing a patient's cancer treatment on commonly disrupted genes and pathways, according to a new study.
Combining high-dose interleukin-2 and personalized vaccines to activate patients' immune systems improves survival of metastatic melanoma even more than IL-2 alone.
Patients with recurrent GBM treated with an experimental vaccine made from the patient's own resected tumor tissue showed an improved survival compared with historical patients who received the standard of care alone, according to an analysis of a phase 2 trial of this vaccine.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|